Juei-Seng Wu

Years Active: 2022-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Hsueh-Chien Chiang, Yang-Cheng Lee, Ting-Tsung Chang, Yih-Jyh Lin, Hung-Tsung Wu, Chung-Teng Wang, Chiung-Yu Chen, Po-Jun Chen, Ming-Tsung Hsieh, Sheng-Hsiang Lin, Shang-Hung Chen, Chiao-Hsiung Chuang, I-Chin Wu, Tzu-Chun Hong, Juei-Seng Wu, Meng-Zhi Han, Wei-Ting Chen, Chien-Ming Chiang, Kuan-Kai Hung, Hsin-Yu Kuo
Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers 15 (3) (2023)
Hsueh-Chien Chiang, Yang-Cheng Lee, Ting-Tsung Chang, Yih-Jyh Lin, Hung-Tsung Wu, Chung-Teng Wang, Chiung-Yu Chen, Po-Jun Chen, Ming-Tsung Hsieh, Sheng-Hsiang Lin, Shang-Hung Chen, Chiao-Hsiung Chuang, I-Chin Wu, Tzu-Chun Hong, Juei-Seng Wu, Meng-Zhi Han, Wei-Ting Chen, Chien-Ming Chiang, Kuan-Kai Hung, Hsin-Yu Kuo
Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers 15 (3) (2023)
Hsin-Yu Kuo, Meng-Zhi Han, Chih-Hsiang Liao, Yih-Jyh Lin, Chung-Teng Wang, Shang-Hung Chen, Ting-Tsung Chang, Po-Jun Chen, Sheng-Hsiang Lin, Chiung-Yu Chen, Chiao-Hsiung Chuang, I-Chin Wu, Juei-Seng Wu, Tzu-Chun Hong, Ming-Tsung Hsieh, Yang-Cheng Lee, Hung-Tsung Wu, Hong-Ming Tsai
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceutics 14 (11) (2022)

Juei-Seng Wu.css-eqlu8i{font-size:small;padding-left:4px;}